In 1992, the US Food and Drug Administration (FDA) introduced the accelerated approval process to allow earlier approval of drugs for serious or life-threatening illnesses on the basis of surrogate end points. This approval requires the drug's sponsor to agree to conduct postmarketing studies proving a benefit in clinical outcomes. Seventy-nine of the 90 drugs approved through this process through 2008 were for treatment of cancer, human immunodeficiency/AIDS, or inhalation anthrax.1 In 1996, midodrine hydrochloride, an α1-adrenergic agonist, was granted accelerated approval for treatment of symptomatic orthostatic hypotension with the guarantee that the drug's sponsor would complete postmarketing studies to demonstrate clinical benefit. On August 16, 2010, noting that these studies had not been conducted, the FDA proposed to withdraw the medication.2 This withdrawal would be a landmark step in protecting the public's health, as it is the agency's first attempt to remove a medication marketed under accelerated approval that had not completed confirmatory trials. However, professional organizations, health care professionals, and patients appealed to the FDA to reverse its decision, and it did so on September 10.3
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 11
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.